CoChat

Chloroquine treatment of ARPE-19 cells leads to lysosome dilation and intracellular lipid accumulation: possible implications of lysosomal dysfunction in macular degeneration

Open access
Chen, Patrick M, Gombart, Zoë J, Chen, Jeff W · 2011 · Cell & Bioscience

The DOI matches its Crossref record; 49 of the 50 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Age-related macular degeneration (AMD) is the leading cause of vision loss in elderly people over 60. The pathogenesis is still unclear. It has been suggested that lysosomal stress may lead to drusen formation, a biomarker of AMD. In this study, ARPE-19 cells were treated with chloroquine to inhibit lysosomal function. RESULTS: Chloroquine-treated ARPE-19 cells demonstrate a marked increase in vacuolation and dense intracellular debris. These are identified as chloroquine-dilated lysosomes and lipid bodies with LAMP-2 and LipidTOX co-localization, respectively. Dilation is an indicator of lysosomal dysfunction. Chloroquine disrupts uptake of exogenously applied rhodamine-labeled dextran by these cells. This suggests a disruption in the phagocytic pathway. The increase in LAMP protein levels, as assessed by Western blots, suggests the possible involvement in autophagy. Oxidative stress with H2O2 does not induce vacuolation or lipid accumulation. CONCLUSION: These findings suggest a possible role for lysosomes in AMD. Chloroquine treatment of RPE cells may provide insights into the cellular mechanisms underlying AMD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/2045-3701-1-10

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Cell Viability Assay. MTT assay shows chloroquine toxicity is both time and dose dependent. Chloroquine concentrations of 10-30 μg/ml (p < 0.05) do not significantly affect cell viability.
Figure 1 Cell Viability Assay. MTT assay shows chloroquine toxicity is both time and dose dependent. Chloroquine concentrations of 10-30 μg/ml (p < 0.05) do not significantly affect cell viability.CC BY · PubMed Central
Figure 2 Cytoplasmic Changes with Chloroquine in ARPE-19. Phase contrast microscopy of ARPE-19 with 0 (A), 10 (B), 20 (C), 40 (D), 80 (E) μg/ml chloroquine. Chloroquine treatment causes membrane-enclosed vacuoles (red arrows) and membranous dense bodies (blue arrows). ARPE treated with high chloroquine dosage show signs of cell death. Bar size = 25 microns.
Figure 2 Cytoplasmic Changes with Chloroquine in ARPE-19. Phase contrast microscopy of ARPE-19 with 0 (A), 10 (B), 20 (C), 40 (D), 80 (E) μg/ml chloroquine. Chloroquine treatment causes membrane-enclosed vacuoles (red arrows) and membranous dense bodies (blue arrows). ARPE treated with high chloroquine dosage show signs of cell death. Bar size = 25 microns.CC BY · PubMed Central
Figure 3 Co-localization of LAMP-2 and LipidTOX. (A-D) Control ARPE-19. (E-H) 20 μg/ml chloroquine-treated ARPE-19. Control phase contrast (A) shows no vacuolation and LAMP-2 (B, green), and LipidTOX(C, red) staining is observed throughout cell. D is fluorescent overlay. Chloroquine-treated cell in phase contrast (E) shows intense vacuolation (white arrows). These vacuoles co-localize with LAMP-2 staining (F, corresponding white arrows). Chloroquine treatment also induces dense body formation (E, yellow arrows). Dense formations co-localize with neutral lipid (G, corresponding yellow arrows). Overlay (H) shows no overlap between lipids and vacuoles. Bar size = 25 microns.
Figure 3 Co-localization of LAMP-2 and LipidTOX. (A-D) Control ARPE-19. (E-H) 20 μg/ml chloroquine-treated ARPE-19. Control phase contrast (A) shows no vacuolation and LAMP-2 (B, green), and LipidTOX(C, red) staining is observed throughout cell. D is fluorescent overlay. Chloroquine-treated cell in phase contrast (E) shows intense vacuolation (white arrows). These vacuoles co-localize with LAMP-2 staining (F, corresponding white arrows). Chloroquine treatment also induces dense body formation (E, yellow arrows). Dense formations co-localize with neutral lipid (G, corresponding yellow arrows). Overlay (H) shows no overlap between lipids and vacuoles. Bar size = 25 microns.CC BY · PubMed Central
Figure 4 Co-localization of LAMP-1 in NIH/3T3. NIH/3T3 cells show a similar pattern of vacuole formation with treatment of chloroquine. Phase contrast and corresponding LAMP-1 co-localization of 25 μg/ml chloroquine-treated cells (C, D) show vacuolation of LAMP-1, when compared with control (A, B). The arrows in C and D note that the borders of the vacuoles correspond with LAMP-1 protein. Bar size = 25 microns.
Figure 4 Co-localization of LAMP-1 in NIH/3T3. NIH/3T3 cells show a similar pattern of vacuole formation with treatment of chloroquine. Phase contrast and corresponding LAMP-1 co-localization of 25 μg/ml chloroquine-treated cells (C, D) show vacuolation of LAMP-1, when compared with control (A, B). The arrows in C and D note that the borders of the vacuoles correspond with LAMP-1 protein. Bar size = 25 microns.CC BY · PubMed Central
Figure 5 Chloroquine Effect on ARPE-19 Golgi and Mitochondria. (A-D) Mitochondria co-localization in (A-B) control and (C-D) 20 μg/ml-treated ARPE-19. There is no difference in MitoTracker staining (red) intensity, shape or localization between control (B) and treatment (D). Similarly, there were no noticeable changes in Golgi apparatus (E-H). Golgi co-localization of control (E-F) and 20 μg/ml chloroquine treatments. Golgi is stained with Golgin-97 antibody staining (green). Bar size = 25 microns.
Figure 5 Chloroquine Effect on ARPE-19 Golgi and Mitochondria. (A-D) Mitochondria co-localization in (A-B) control and (C-D) 20 μg/ml-treated ARPE-19. There is no difference in MitoTracker staining (red) intensity, shape or localization between control (B) and treatment (D). Similarly, there were no noticeable changes in Golgi apparatus (E-H). Golgi co-localization of control (E-F) and 20 μg/ml chloroquine treatments. Golgi is stained with Golgin-97 antibody staining (green). Bar size = 25 microns.CC BY · PubMed Central
Figure 6 Phagocytic Activity and LAMP Protein. (A) Comparisons of LAMP-1 and LAMP-2 protein levels at different concentrations of chloroquine. Protein levels measured in ARPE-19 by Western blot with beta-actin as loading control. Western shows marked qualitative increase in LAMP 1-2 band size between control and 10 μg/ml chloroquine treatment, while loaded control is constant. (B) There is a significant increase in LAMP-1 and 2 (p < 0.05) at 10 μg/ml with overall upregulation trend response to chloroquine treatment. Immunoblots (n = 6) were scanned, and densitometry was performed on bands with ImageJ (NIH, Bethesda MD). Relative band density measurement was repeated several times to ensure maximum and minimum values.
Figure 6 Phagocytic Activity and LAMP Protein. (A) Comparisons of LAMP-1 and LAMP-2 protein levels at different concentrations of chloroquine. Protein levels measured in ARPE-19 by Western blot with beta-actin as loading control. Western shows marked qualitative increase in LAMP 1-2 band size between control and 10 μg/ml chloroquine treatment, while loaded control is constant. (B) There is a significant increase in LAMP-1 and 2 (p < 0.05) at 10 μg/ml with overall upregulation trend response to chloroquine treatment. Immunoblots (n = 6) were scanned, and densitometry was performed on bands with ImageJ (NIH, Bethesda MD). Relative band density measurement was repeated several times to ensure maximum and minimum values.CC BY · PubMed Central
Figure 7 Phagocytic Activity Measured by Dextran Uptake. (A-B) Immunofluorescence of exogenous rhodamine-labeled dextran (red) uptake with ImageJ markings (crosshairs) of counted dextran maximas. 20 μg/ml chloroquine-treated cells at 24 hours (B) showed striking decrease in fluorescent dextran uptake when compared to control (A). (C) Quantization of dextran uptake between control and chloroquine-treated ARPE-19. There is a significant (p < 0.05) decrease in relative dextran uptake in individual sampled ARPE-19 cells between control and chloroquine-treated cells. Quantitation was performed by using ImageJ, isolating cells of relative same size (~20-25 microns), and then calculating florescent maximas (tolerance = 20, based on control). Maximas were averaged and standard t-test was performed (n = 10).
Figure 7 Phagocytic Activity Measured by Dextran Uptake. (A-B) Immunofluorescence of exogenous rhodamine-labeled dextran (red) uptake with ImageJ markings (crosshairs) of counted dextran maximas. 20 μg/ml chloroquine-treated cells at 24 hours (B) showed striking decrease in fluorescent dextran uptake when compared to control (A). (C) Quantization of dextran uptake between control and chloroquine-treated ARPE-19. There is a significant (p < 0.05) decrease in relative dextran uptake in individual sampled ARPE-19 cells between control and chloroquine-treated cells. Quantitation was performed by using ImageJ, isolating cells of relative same size (~20-25 microns), and then calculating florescent maximas (tolerance = 20, based on control). Maximas were averaged and standard t-test was performed (n = 10).CC BY · PubMed Central
Figure 8 Oxidative Stress Test. (A) phase contrast, (B) LAMP-2 and (C) LipidTOX staining of 10 mM hydrogen peroxide-treated ARPE-19. (D) Overlay showing co-localization of neutral lipid and LAMP-2. There are no differences in cell cytoplasm (vacuoles, lipids) in phase or fluorescence between control (Fig 2 A-D) and hydrogen peroxide treatment.
Figure 8 Oxidative Stress Test. (A) phase contrast, (B) LAMP-2 and (C) LipidTOX staining of 10 mM hydrogen peroxide-treated ARPE-19. (D) Overlay showing co-localization of neutral lipid and LAMP-2. There are no differences in cell cytoplasm (vacuoles, lipids) in phase or fluorescence between control (Fig 2 A-D) and hydrogen peroxide treatment.CC BY · PubMed Central
Figure 9 Possible LAMP-2/Lysosomal Inhibition Model of Pathogenesis of AMD. An unknown cause results in loss of the protective glycocalyx of LAMP-2. Proteolysis of LAMP-2 occurs. Loss of LAMP-2 results in either 1) A pH shift and loss of acidity of lysosome, 2) dynein no longer moving late phagosome to microtubule sorting center near Golgi for fusion with lysosome or 3) perturbation of M6PR/Rab recycling such that M6PR/Rab7 does not tag late endosomes. The loss of functionality of M6PR/Rab7 results in a lack of phagosome lysosome-fusion. Any of these results in loss of the lysosome's ability to degrade intra- and extracellular material. Subsequently, undegraded material is oxidized, turning to lipofuscin. Ultimately, the combination of oxidative stress, Fe+ accumulation, senile mitochondria and decrease in ATP results in inefficient turnover of organelles and increased inhibition of lysosomes. RPE death triggers photoreceptor and macula death.
Figure 9 Possible LAMP-2/Lysosomal Inhibition Model of Pathogenesis of AMD. An unknown cause results in loss of the protective glycocalyx of LAMP-2. Proteolysis of LAMP-2 occurs. Loss of LAMP-2 results in either 1) A pH shift and loss of acidity of lysosome, 2) dynein no longer moving late phagosome to microtubule sorting center near Golgi for fusion with lysosome or 3) perturbation of M6PR/Rab recycling such that M6PR/Rab7 does not tag late endosomes. The loss of functionality of M6PR/Rab7 results in a lack of phagosome lysosome-fusion. Any of these results in loss of the lysosome's ability to degrade intra- and extracellular material. Subsequently, undegraded material is oxidized, turning to lipofuscin. Ultimately, the combination of oxidative stress, Fe+ accumulation, senile mitochondria and decrease in ATP results in inefficient turnover of organelles and increased inhibition of lysosomes. RPE death triggers photoreceptor and macula death.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 49 references

Cited by

See all 122

Metadata

Authors
Chen, P. M., Gombart, Z. J., & Chen, J. W.
Affiliations
Legacy Health (US)
Venue
Cell & Bioscience
Published
2011
Volume
1
Issue
1
Pages
10
ISSN
2045-3701 (ISSN-L)
OpenAlex
W2156411936
Cited by
122
References
50
Citations by year
2026: 2 · 2025: 5 · 2024: 12 · 2023: 7 · 2022: 9 · 2021: 16 · 2020: 9 · 2019: 6 · 2018: 9 · 2017: 11 · 2016: 4 · 2015: 9 · 2014: 6 · 2013: 8 · 2012: 6
FWCI
6.90
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Cell & Bioscience (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Dartmouth College
Topics
  • Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Autophagy in Disease and Therapy
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Cellular transport and secretion
Keywords
age-related macular degeneration, lysosomal dysfunction, chloroquine, ARPE-19 cells, retinal pigment epithelium, intracellular lipid accumulation, lipid droplets, drusen formation, phagocytosis, autophagy, LAMP2, oxidative stress, lysosomal stress

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Chloroquine treatment of ARPE-19 cells leads to lysosome dilation and intracellular lipid accumulation: possible implications of lysosomal dysfunction in macular degeneration. https://app.cochat.ai/papers/10.1186/2045-3701-1-10
The paper
Chen, P. M., Gombart, Z. J., & Chen, J. W. (2011). Chloroquine treatment of ARPE-19 cells leads to lysosome dilation and intracellular lipid accumulation: possible implications of lysosomal dysfunction in macular degeneration. Cell & Bioscience. https://doi.org/10.1186/2045-3701-1-10

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.